insights_auto
Why is ABVX down 3.35%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
€73.55
arrow_downward
-3.35%(-2.55) 1D
Nov 20, 10:33:01 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€74.50
High
€74.50
Low
€73.30
Mkt. cap
6.44B
Avg. vol.
112.96K
Volume
16.93K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€74.50
High
€74.50
Low
€73.30
Mkt. cap
6.44B
Avg. vol.
112.96K
Volume
16.93K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
The Motley Fool
·
42 minutes ago
Nvidia Has Lost More Than the Market Value of 495 S&P 500 Companies in 6 Weeks -- and Its Downtrend May Be Just Beginning
Yahoo Finance
·
20 minutes ago
Stock market today: Dow, S&P 500, Nasdaq futures continue to sell-off after Anthropic IPO fails to quell AI worries
BeInCrypto
·
48 minutes ago
S&P 500 Logs Its Longest Losing Streak Since 2024. Here’s What Happened Last Time
Investing.com
·
1 hour ago
S&P 500 Breaks Support as Global Risk Sentiment Begins to Crack
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com